Researchers: Merck's RotaTeq benefits unvaccinated children

Rates of hospitalization and emergency room visits among children due to rotavirus infection fell between 80% and 100% since the launch of Merck & Co.'s RotaTeq in 2006, according to studies from the CDC and Quest Diagnostics. The oral vaccine -- which is given to patients at ages 2 months, 4 months and 6 months -- also appeared to prevent the spread of the disease in older unvaccinated children, an expert on infectious diseases said.

View Full Article in:

Washington Post (tiered subscription model), The · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ